LC-MS analysis of trimethoxyamphetamine designer drugs (TMA series) from urine samples

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 867, Issue 1, 2008, Pages 126-130

  Nieddu, Maria ^a   Boatto, Gianpiero ^a   Pirisi, Maria Antonietta ^a   Azara, Emanuela ^b   Marchetti, Mauro ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b CNR   (Italy)

Author keywords

Designer drugs; Human urine; Liquid chromatography; Mass spectrometry; TMA series; Trimethoxyamphetamines

Indexed keywords

ACETONITRILE; BIOMEDICAL ENGINEERING; BODY FLUIDS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

DESIGNER DRUGS; DRUG TESTING; HUMAN URINE; TRIMETHOXYAMPHETAMINES;

DRUG PRODUCTS;

DESIGNER DRUG; PSYCHEDELIC AGENT; TRIMETHOXYAMPHETAMINE;

ARTICLE; CHROMATOGRAPHY; DIAGNOSTIC ACCURACY; DRUG SCREENING; ELECTROSPRAY MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; STRUCTURE ACTIVITY RELATION; URINALYSIS;

AMPHETAMINES; CHROMATOGRAPHY, LIQUID; DESIGNER DRUGS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 42749085372     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2008.03.027     Document Type: Article

References (23)

1. Shulgin A. Psychotomimetic Drugs: Structure-Activity Relationships in Handbook of Psychopharmacology Stimulants 11 (1978), Plenum Press, New York
2. Shulgin A., and Shulgin A. Pihkal. A Chemical Love Story. first ed. (1998), Transform Press, Berkeley
3. Weltman A.S., Sackler A.M., Pandhi V., and Johnson L. Experientia 32 (1976) 357
4. European Monitoring Centre for Drugs and Drug Addiction: Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs; Lisbon, EMCDDA, 2004, www.emcdda.eu.int.
5. Council Decision 2003/847/JHA, Official Journal of European Union series JO/L321, 2003, 46, 64; http://eur-lex.europa.eu.
6. Tsujikawa K., Kanamori T., Kuwayama K., Miyaguchi H., Iwata Y., and Inoue H. DEA Res., Microgram J. 4 (2006) 12
7. Ewald A.H., Fritschi G., and Maurer H.H. J. Mass Spectrom. 41 (2006) 1140
8. Nordgren H.K., and Beck O. J. Anal. Toxicol. 27 (2003) 15
9. Mortier K.A., Dams R., Lambert W.E., De Letter E.A., Van Calenbergh S., and Leenheer A.P. Rapid Commun. Mass Spectrom. 16 (2002) 865
10. Sato M., Hida M., and Nagase H. For. Sci. Int. 128 (2002) 146
11. Chou C.C., and Lee M.R. Anal. Chim. Acta 538 (2005) 49
12. Deventer K., Van Eenoo P., and Delbeke F.T. Rapid Commun. Mass Spectrom. 26 (2006) 877
13. Laks S., Pelander A., Vuori E., Ali-Tolppa E., Sippola E., and Ojanpera I. Anal. Chem. 76 (2004) 7375
14. Boatto G., Nieddu M., Carta A., Pau A., Asproni B., and Cerri R. J. Chromatogr. B 814 (2005) 93
15. Nieddu M., Boatto G., Sini L., and Dessì G. J. Liq. Chromatogr. Relat. Technol. 30 (2007) 431
16. Nieddu M., Boatto G., and Dessì G. J. Chromatogr. B 852 (2007) 578
17. Peters F.T., and Maureer H.H. Accred. Qual. Assur. 7 (2002) 441
18. Taverniers I., de Loose M., and Van Bockstaele E. Trend Anal. Chem. 23 (2004) 535
19. Annesley T. Clin. Chem. 49 (2003) 1041
20. Rockville M.D. U.S. Pharmacopoeia & National Formulary (USP 24/NF19). Validation of Compendial Methods (1999), United States Pharmacopeial Convention Inc. pp. 2149
21. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2001. http://www.fda.gov/cder/guidance/4252fnl.htm.
22. Mandatory guideline for Federal workplace drug testing programs: notice, Federal Register, 69 (2004) 19644.
23. Frison G., Tedeschi L., Favretto D., Reheman A., and Ferrara S.D. Rapid Commun. Mass Spectrom. 19 (2005) 919